Filings/MAB/IR

MABION S.A. IR

press release · 2025

Leading european biologics CDMO Mabion, releases first batch of Novalgen’s next-generation T-cell engager, NVG-222 for first in-human clinical trials 17.06.2025 Learn more

Source document

Issuer site
Loading document…
Leading european biologics CDMO Mabion, releases first batch of Novalgen’s next-generation T-cell engager, NVG-222 for first in-human clinical trials 17.06.2025 Learn more — MABION S.A.